Multicenter comparison of 18F-FDG and 68Ga-DOTA-peptide PET/CT for pulmonary carcinoid

Filippo Lococo, Germano Perotti, Giuseppe Cardillo, Chiara De Waure, Angelina Filice, Paolo Graziano, Giulio Rossi, Giorgio Sgarbi, Antonella Stefanelli, Alessandro Giordano, Pierluigi Granone, Guido Rindi, Annibale Versari, Vittoria Rufini

Research output: Contribution to journalArticle

Abstract

PURPOSE: The aims of this study were to retrospectively evaluate and compare the detection rate (DR) of Ga-DOTA-peptide and F-FDG PET/CT in the preoperative workup of patients with pulmonary carcinoid (PC) and to assess the utility of various functional indices obtained with the 2 tracers in predicting the histological characterization of PC, that is, typical versus atypical. METHODS: Thirty-three consecutive patients with confirmed PC referred for F-FDG and Ga-DOTA-peptide PET/CT in 2 centers between January 2009 and April 2013 were included. The semiquantitative evaluation included the SUVmax, the SUV of the tumor relative to the maximal liver uptake for F-FDG (SUVT/L) or the maximal spleen uptake for Ga-DOTA-peptides (SUVT/S), the ratio between SUVmax of Ga-DOTA-peptides PET/CT, and the SUVmax of F-FDG PET/CT (SUVmax ratio). Histology was used as reference standard. RESULTS: Definitive diagnosis consisted of 23 typical carcinoids (TCs) and 10 atypical carcinoids. F-FDG PET/CT was positive in 18 cases and negative in 15 (55% DR). Ga-DOTA-peptide PET/CT was positive in 26 cases and negative in 7 (79% DR). In the subgroup analysis, Ga-DOTA-peptide PET/CT was superior in detecting TC (91% DR; P <0.001), whereas F-FDG PET/CT was superior in detecting atypical carcinoid (100% DR; P = 0.04). The SUVmax ratio was the most accurate semiquantitative index in identifying TC. CONCLUSIONS: Overall diagnostic performance of PET/CT in detecting PC is optimal when integrating F-FDG and Ga-DOTA-peptide PET/CT findings. In the subgroup analysis, the SUVmax ratio seems to be the most accurate index in predicting TC. Both methods should be performed when PC is suspected or when the histological subtype is undefined.

Original languageEnglish
Pages (from-to)e183-e189
JournalClinical Nuclear Medicine
Volume40
Issue number3
DOIs
Publication statusPublished - Mar 13 2015

Keywords

  • F-FDG
  • Ga-DOTA-peptides
  • PET/CT
  • pulmonary carcinoid

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Fingerprint Dive into the research topics of 'Multicenter comparison of 18F-FDG and 68Ga-DOTA-peptide PET/CT for pulmonary carcinoid'. Together they form a unique fingerprint.

  • Cite this

    Lococo, F., Perotti, G., Cardillo, G., De Waure, C., Filice, A., Graziano, P., Rossi, G., Sgarbi, G., Stefanelli, A., Giordano, A., Granone, P., Rindi, G., Versari, A., & Rufini, V. (2015). Multicenter comparison of 18F-FDG and 68Ga-DOTA-peptide PET/CT for pulmonary carcinoid. Clinical Nuclear Medicine, 40(3), e183-e189. https://doi.org/10.1097/RLU.0000000000000641